DEPARTMENT OF HUMAN SERVICES

Meeting Minutes: Drug Formulary Committee (DFC) - DRAFT

Date and Time: March 18, 2026: 9:15a.m. – 1:30 p.m. (Central Time)
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2370

Attendance

- Members in attendance: Arthur Beisang, MD; Jacques Beasley; Mary Mescher Benbenek, PhD, APRN; Jeannine Conway, PharmD; Katherine Montag Schafer, PharmD; Emma Ryan, PharmD; Kelly Ruby, PharmD; Sheila Scheuer, PharmD; Romie Tinsay, MD; Sandra Widhalm Murphy, RPh; Stuart Williams, JD
  Members absent: Emily Jaeger, PharmD; Jena Wirt, DO; Julie Wolfgram, DNP, FNP
- DHS staff present: Chad Hope, PharmD; Dave Hoang, PharmD, MBA; Aaron Drake, RPh; Erin Neumann, PharmD
- Others in attendance: Naana Osei-Boateng, PharmD; Chloe Groomes, PharmD; Andrew Wherley, PharmD; Laura Pounders, PharmD

Election

- Stuart Williams was re-elected Chair of the DFC.
- Kelly Ruby was re-elected Vice Chair of the DFC.

Report of the Chair

- Stuart Williams presided over the meeting. Approval of Minutes

Approval of Minutes

- The DFC approved the minutes from the December 2025 meeting.

DHS Housekeeping

- DHS reminded all in attendance that the meeting agenda and materials are available on the DFC webpage at least 30 days prior to the public meeting. Members of the general public can sign up to receive DFC related communications including the meeting agenda and materials directly from the agency.

Old Business

- None

New Business:

New Specialty Drugs for Continued PA

- The committee discussed Ycanth and recommended to DHS by a unanimous vote that Ycanth remain on PA with the following amendment to the proposed criteria:
    - Approval criteria, bullet point #6; sub bullet #1; be changed to: "Tried and had an inadequate response to ONE conventional therapy (e.g ~~cantharidin~~, cryotherapy, curettage, podofilox) …"

- The committee discussed Papzimeos and recommended to DHS by a unanimous vote that Papzimeos remain on PA with the following amendment to the proposed criteria:
    - Approval criteria, bullet point #2 be changed to: "Patient has a confirmed histological diagnosis of recurrent respiratory papillomatosis "…*with HPV 6 or HPV 11."*

- The committee discussed Wayrilz and recommended to DHS by a unanimous vote that Wayrilz remain on PA with the proposed criteria.

- The committee discussed Blujepa and recommended to DHS by a unanimous vote that Blujepa remain on PA with the following amendment to the proposed criteria:
    - Addition of an additional quantity limit bullet for Uncomplicated Urogenital Gonorrhea of: "8 tablets/course (3000 mg [four 750 mg tablets] to start followed by 4 tablets 12 hours later and may not be renewed
    - Insertion of the following as 4th bullet point under approval criteria: "The patient has a diagnosis of uncomplicated urogenital gonorrhea and has limited or no alternative treatment options…"

- The committee discussed Jascayd and recommended to DHS by a unanimous vote that Jascayd remain on PA with the proposed criteria.

- The committee discussed Palsonify and recommended to DHS by a unanimous vote that Palsonify remain on PA with the proposed criteria:

- The committee discussed Tavalisse and recommended to DHS by a unanimous vote that Tavalisse remain on PA with the proposed criteria.

- The committee discussed Rhapsido and recommended to DHS by a majority vote that Rhapsido remain on PA with the proposed criteria.

- The committee discussed Lynkuet and recommended to DHS by a unanimous vote that Lynkuet remain on PA with the proposed criteria.

Existing Specialty Drugs for Continued PA

- The committee discussed Zoryve foam and Zoryve 0.3% cream and recommended to DHS by a unanimous vote that the products remain on PA with the proposed updated criteria.

- The committee discussed Wakix and recommended to DHS by a unanimous vote that Wakix remain on PA with the proposed updated criteria.

- The committee discussed PCSK9 inhibitors and recommended to DHS by a unanimous vote that Praluent and Repatha remain on PA with the proposed updated criteria.

90-day Supply Drug List Review

- The committee reviewed the revised FFS MA's 90-day supply drug list and recommended it to DHS by a majority vote with the following amendment:
  Add the following antimalarial medications: atorvaquone/proguanil tablet, mefloquine tablet and doxycycline capsule.

Preferred Drug List (PDL) Review

DISCUSSION ITEMS:

- The committee discussed the Alzheimer's Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - MEMANTINE/DONEPEZIL ER CAP (ORAL) and ZUNVEYL (ORAL) added to the PDL to as NONPREFERRED.

- The committee discussed the Angiotensin Modulator Combinations therapeutic class and recommended the following to the department by a unanimous vote:
    - OLMESARTAN/AMLODIPINE/HCTZ (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Angiotensin Modulators therapeutic class and recommended the following to the department by a unanimous vote:
    - SACUBITRIL-VALSARTAN (ORAL) to be added to the PDL as PREFERRED.
    - ENTRESTO (ORAL) to be moved on the PDL to NONPREFERRED.
    - ARBLI SUSPENSION (ORAL) and VALSARTAN SOLUTION (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Anticonvulsants therapeutic class and recommended the following to the department by a unanimous vote:
    - BRIVARACETAM TABLET (ORAL) and CARBATROL (ORAL) to be added to the PDL as PREFERRED.
    - OXCARBAZEPINE ER (ORAL), SUBVENITE SUSPENSION (ORAL) and TOPIRAMATE SOLUTION (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the Antiparkinson's Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - APOKYN (SUBCUTAENOUS) to be to be added to the PDL as PREFERRED.
    - APOMORPHINE (SUBCUTANEOUS), CREXONT CAPSULE ER (ORAL) and ONAPGO (SUBCUTANEOUS) to be to be added to the PDL as NONPREFERRED.

- The committee discussed the Immunomodulators, Atopic Dermatitis therapeutic class and recommended the following to the department by a unanimous vote:
    - ANZUPGO CREAM (TOPICAL) and ZORYVE 0.05% CREAM to be added to the PDL as NONPREFERRED.

- The committee discussed the Multiple Sclerosis Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - DALFAMPRIDINE ER (ORAL) to be moved on the PDL to PREFERRED.
    - CLADRIBINE (ORAL) and TYRUKO (INTRAVEN.) to be added to the PDL as NONPREFERRED.

- The committee discussed the Opiate Dependence Treatments therapeutic class and recommended the following to the department by a unanimous vote:
    - ZURNAI (INJECTION) to be added to the PDL as NONPREFERRED.
    - ZIMHI (INJECTION) to be removed from the PDL.

CONSENT AGENDA ITEMS:
The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items be approved as presented.

Adjournment

- The meeting was adjourned at approximately 1:04 pm Central Time.